 we are off to a strong start to the year, with total revenues of approximately $5.6 billion and adjusted earnings per share of approximately $2.46, both exceeding our expectations. 
 this performance was driven by double-digit sales growth from several key products including, Skyrizi, Rinvoq, Venclexta, and Vraylar, positive momentum from our aesthetics business, and strong results internationally, and stabilizing consumer trends in the U.S. in the first quarter of this year. 
 we also continue to see strong performance across our therapeutic portfolio, including the launch of new products and expanded indications, especially across Skyrizi and Rinvoq, and recently with Vraylar in MDD. in oncology, we continue to make good progress across all stages of our hematology and solid tumor pipelines, including regulatory approval for Epcoritamab in relapsed refractory large b cell lymphoma. 
 we also recently announced positive top line results from our induction study for Skyrizi in ulcerative colitis, which is a disease with unpredictable symptoms and frequent players making it challenging to manage. in immunology, we recently received European approval for Rinvoq in Crohn s disease,